IL6 and congenital rubella syndrome: In addition, elevated IL-6 levels are considered as the hallmark of cytokine-release syndrome (CRS) (40), a common side effect of CAR-T therapy, and the reduced IL-6 releasing observed in SAP UCAR-T cells suggested a lower risk of safety issues (Figure 5E).